Archives: Search / 2017 / 2016 / 2015 / 2014 / 2013 / 2012 / 2011 / 2010 / 2009 / 2008

200720062004

2017 Archives

Oct 2, 2017
--Company Cleared to Market Prescription and OTC Generic Prevacid®--

Lannett Company, Inc. (NYSE: LCI) today announced that it received approval from the U.S. Food and Drug Administration (FDA) of its Abbreviated New Drug Application (ANDA) for Lansoprazole...

More
Sep 27, 2017

Lannett Company, Inc. (NYSE: LCI) today announced that it received approval from the U.S. Food and Drug Administration (FDA) of its Abbreviated New Drug Application (ANDA) for Oxycodone and...

More
Sep 26, 2017

Lannett Company, Inc. (NYSE: LCI) today announced that it received approval from the U.S. Food and Drug Administration (FDA) of its Abbreviated New Drug Application (ANDA) for Dexmethylphenidate...

More
Sep 26, 2017

Lannett Company, Inc. (NYSE: LCI) today announced that the United States District Judge for the Eastern District of Pennsylvania dismissed in its entirety a putative class action lawsuit against a...

More
Sep 25, 2017
--CEO Arthur Bedrosian to Step Down Upon Naming of a Successor--

Lannett Company, Inc. (NYSE: LCI) today announced that its board of directors has begun a search for a new chief executive officer (CEO). As part of the unanimously approved search process, the...

More
Sep 22, 2017

Arthur Bedrosian, chief executive officer of Lannett Company, Inc. (NYSE: LCI), has prevailed in his lawsuit with the U.S. Internal Revenue Service (IRS). Bedrosian filed a lawsuit against the...

More
Sep 5, 2017

Lannett Company, Inc. (NYSE: LCI) today announced that it received approval from the U.S. Food and Drug Administration (FDA) of its Abbreviated New Drug Application (ANDA) for Esomeprazole...

More
Aug 23, 2017

Lannett Company, Inc. (NYSE: LCI) today reported financial results for its fiscal 2017 fourth quarter and full year ended June 30, 2017. "In the coming year, we expect a solid increase in net...

More
Aug 8, 2017
--Company to Report Full Financial Results and Host Conference Call on August 23--

Lannett Company, Inc. (NYSE: LCI) today reported preliminary financial results for its fiscal 2017 fourth quarter and full year ended June 30, 2017. "While our industry is currently facing...

More
Aug 1, 2017

Lannett Company, Inc. (NYSE: LCI) today announced that the company will present at the Canaccord Genuity 37th Annual Growth Conference on August 9, 2017 at 4 p.m. (ET) at the InterContinental Hotel in

More
Jul 17, 2017

Lannett Company, Inc. (NYSE: LCI) today announced the appointment of Samuel H. Israel as vice president, chief legal officer and general counsel. "I am very pleased to welcome Sam to the Lannett...

More
Jul 14, 2017

Lannett Company, Inc. (NYSE: LCI) today announced that it received approval from the U.S. Food and Drug Administration (FDA) of its Abbreviated New Drug Application (ANDA) for Cyproheptadine...

More
Jun 26, 2017
--New Dosage Strengths of 5 mg/325 mg, 7.5 mg/325 mg and 10 mg/325 mg Represent Lion's Share of the Market and Complement Previously Approved Dosage Strengths--

Lannett Company, Inc. (NYSE: LCI) today announced that it received approval from the U.S. Food and Drug Administration (FDA) of its Abbreviated New Drug Application (ANDA) for Hydrocodone...

More
Jun 22, 2017

Lannett Company, Inc. (NYSE: LCI) today announced that it received approval from the U.S. Food and Drug Administration (FDA) of its Abbreviated New Drug Application (ANDA) for Hydrocodone...

More
Jun 20, 2017

Lannett Company, Inc. (NYSE: LCI) today announced that Patrick G. LePore has been appointed to the company's Board of Directors, effective July 1, 2017. The addition of LePore will increase the...

More
Jun 19, 2017

Lannett Company, Inc. (NYSE: LCI) today announced that it received approval from the U.S. Food and Drug Administration (FDA) of its Abbreviated New Drug Application (ANDA) for Niacin...

More
Jun 16, 2017

Lannett Company, Inc. (NYSE: LCI) today announced that it received approval from the U.S. Food and Drug Administration (FDA) of its Abbreviated New Drug Application (ANDA) for Amantadine...

More
May 26, 2017

Lannett Company, Inc. (NYSE: LCI) today announced that its chief executive officer, Arthur Bedrosian, received a top rating in a report by Owler, the world's largest community-based business...

More
May 16, 2017

Lannett Company, Inc. (NYSE: LCI) today announced that it received approval from the U.S. Food and Drug Administration (FDA) of its Abbreviated New Drug Application (ANDA) for Levocetirizine...

More
May 9, 2017

Lannett Company, Inc. (NYSE: LCI) today announced that the company voluntarily paid down the remaining principal balance of $25 million against its existing revolving credit facility. "Since...

More
May 2, 2017

Lannett Company, Inc. (NYSE: LCI) today reported financial results for its fiscal 2017 third quarter ended March 31, 2017. "Net sales in our fiscal 2017 third quarter increased compared with the...

More
Apr 28, 2017

Lannett Company, Inc. (NYSE: LCI) today announced its participation at three upcoming investor conferences. These include the: Deutsche Bank 42nd Annual Health Care Conference at 8 a.m. ET, on...

More
Apr 25, 2017

Lannett Company, Inc. (NYSE: LCI) today announced that it will report financial results for its fiscal 2017 third quarter on Tuesday, May 2, 2017, after the market closes. Lannett management will...

More
Mar 30, 2017

Lannett Company, Inc. (NYSE: LCI) today announced that the company voluntarily made a $25 million payment against its existing revolving credit facility. "This $25 million payment, combined with...

More
Mar 27, 2017

Lannett Company, Inc. (NYSE: LCI) today announced that its former chairman and chief executive officer William (Bill) Farber, R. Ph., has passed away from natural causes. Mr. Farber served as the...

More
 

print email rss
Lannett Investor Relations
Lannett Company Products